Central Garden & Pet Company (CENT) Income Statement

The -8.2% YoY decline in Q3 2026 is the steepest drop in the last eight quarters, following a -3.6% decline in the prior year's same quarter. This suggests the strategic exit from pet distribution is accelerating the top-line contraction, though the sequential improvement from Q1 2026 (-6.0%) indicates some stabilization. The revenue base is shifting toward higher-margin proprietary brands, but the near-term growth trajectory remains pressured as the company trades volume for profitability.

The gross margin improvement from 34.6% in Q3 2025 to 35.9% in Q3 2026 is notable, especially given the revenue decline. This suggests the company is successfully shifting toward higher-margin proprietary products, but the sustainability of this expansion depends on the company's ability to maintain pricing power amid private label competition. The sequential improvement from 33.1% in Q2 2026 indicates that the margin gains are not just seasonal, but the absolute level remains below peers like Spectrum Brands (36.7%), suggesting room for further optimization.

The operating income of $125.8M in Q3 2026 represents a 14.3% margin, which is the highest in the last ten quarters, despite the revenue contraction. This suggests that the company is achieving operating leverage through cost discipline and a favorable product mix. However, the SG&A line of $191.1M is still elevated relative to the revenue base, and the company's ability to sustain this leverage will be tested if revenue continues to decline. The sequential improvement from 12.6% in Q2 2026 indicates that the margin expansion is gaining momentum.

The SG&A expense of $191.1M in Q3 2026 is only 3.1% higher than the prior year's $196.9M, while revenue declined 8.2%, resulting in a 120 basis point improvement in SG&A as a percentage of revenue. This suggests that management is effectively controlling overhead costs, possibly through the simplification of the distribution network. However, the absolute SG&A remains high, and the company's ability to maintain this discipline will be crucial as it navigates the revenue decline. The R&D line is zero, indicating that the company does not invest heavily in innovation, which could limit long-term differentiation.

The combination of record gross and operating margins in Q3 2026, despite a revenue decline, suggests that the company's portfolio reshaping is yielding tangible benefits. The exit of the pet distribution business appears to have removed low-margin revenue, allowing the remaining proprietary brands to drive profitability. This inflection is supported by the sequential improvement from Q2 2026, where margins were 33.1% and 12.6%, respectively. However, the sustainability of this inflection depends on the company's ability to maintain pricing power and cost discipline in the face of private label competition and potential commodity cost inflation.